188 related articles for article (PubMed ID: 9867152)
1. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.
van Rensburg AJ; Alberts AS; Louw WK
J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152
[TBL] [Abstract][Full Text] [Related]
2. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
3. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
5. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Cameron PJ; Klemp PF; Martindale AA; Turner JH
Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
Bayouth JE; Macey DJ; Kasi LP; Fossella FV
J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
[TBL] [Abstract][Full Text] [Related]
7. Samarium-153-EDTMP biodistribution and dosimetry estimation.
Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
[TBL] [Abstract][Full Text] [Related]
8. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.
Singh A; Holmes RA; Farhangi M; Volkert WA; Williams A; Stringham LM; Ketring AR
J Nucl Med; 1989 Nov; 30(11):1814-8. PubMed ID: 2478681
[TBL] [Abstract][Full Text] [Related]
9. Samarium for osteoblastic bone metastases and osteosarcoma.
Anderson P
Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
[TBL] [Abstract][Full Text] [Related]
10. ESR dosimetry of 89Sr and 153Sm in bone.
Kinoshita A; Braga FJ; Graeff CF; Baffa O
Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
[TBL] [Abstract][Full Text] [Related]
11. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
[TBL] [Abstract][Full Text] [Related]
12. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
[TBL] [Abstract][Full Text] [Related]
13. The importance of BMI in dosimetry of
Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F
Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122
[TBL] [Abstract][Full Text] [Related]
14. A pilot study on the feasibility of real-time calculation of three-dimensional dose distribution for (153)Sm-EDTMP radionuclide therapy based on the voxel S-values.
Feng G; Lixin C; Xiaowei L; Tsao SY; Weiguang Z; Wei F
Cancer Biother Radiopharm; 2010 Jun; 25(3):345-52. PubMed ID: 20578840
[TBL] [Abstract][Full Text] [Related]
15. Samarium-153-EDTMP in bone metastases.
Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
[TBL] [Abstract][Full Text] [Related]
16. 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
Knop S; Dohmen BM; Kanz L; Bares R; Einsele H
Haematologica; 2004 Sep; 89(9):ECR36. PubMed ID: 15377488
[No Abstract] [Full Text] [Related]
17. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
Dolezal J; Vizd'a J; Cermáková E
Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
[TBL] [Abstract][Full Text] [Related]
19. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
[TBL] [Abstract][Full Text] [Related]
20. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
